PL
 |
EN
Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl
Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 16

Liczba wyników na stronie
first rewind previous Strona / 1 next fast forward last
Wyniki wyszukiwania
Wyszukiwano:
w słowach kluczowych:  interstitial lung disease
help Sortuj według:

help Ogranicz wyniki do:
first rewind previous Strona / 1 next fast forward last
1
Content available Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review
100%
Buraczewska A. , Kardas J.
OncoReview
|
2015
|
tom 5
|
nr 3
A117-121
EN
We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurred in the form of a drug-induced interstitial lung disease. We also provide a review of the literature concerning opinions on incidence, clinical picture, consequences and management of the complication discussed.
2
Content available Pulmonary lymphangitic carcinomatosis in the course of gastric cancer - Case report
100%
Witczak A. , Prystupa A. , Zamecka M. O. , Bilan A. , Krupski W. , Mosiewicz J.
Journal of Pre-Clinical and Clinical Research
|
2014
|
tom 08
|
nr 2
EN
Pulmonary lymphangitic carcinomatosis is a special type of diffuse metastasis of carcinoma in the lymphatic vessels of the lungs. Lymphangitic carcinomatosis is commonly observed in malignancies of the breast, lung, pancreas, colon and cervix as a strong marker for poor prognosis. Presenting with common respiratory symptoms, it may be easily misdiagnosed as other pulmonary interstitial diseases. Pulmonary lymphangitic carcinomatosis is a rare manifestation of metastatic gastric cancer. The presented case describes a patient with pulmonary lymphangitic carcinomatosis in the course of stomach cancer. The primary diagnosis was established based on the exclusion of other interstitial lung diseases, with the use of imaging techniques as well as biochemical, microbiological and cytological findings. The patient’s general condition was very severe, rendering him bedridden and therefore not eligible for any treatment, including chemotherapy. He died suddenly before final verification of the diagnosis. Pulmonary lymphangitic carcinomatosis should be suspected in patients with advanced gastric cancer, presenting with symptoms and signs of respiratory disease. Imaging techniques are mostly helpful to establish the diagnosis.
3
Content available remote Right ventricular function in patients with severe interstitial lung disease: a tissue Doppler imaging study
75%
Nowak J. , Jastrzebski D. , Streb W. , Rozentryt P. , Wojarski J. , Greif M. , Kozielski J. , Polonski L. , Zembala M. , Kukulski T.
Journal of Physiology and Pharmacology. Supplement
|
2008
|
tom 59
|
nr 6
531-538
4
Content available remote Role of bronchoalveolar lavage in the initial diagnosis of smoking-related interstitial lung diseases
75%
Domagala-Kulawik J. , Maskey-Warzechowska M. , Krenke R. , Chazan R.
Journal of Physiology and Pharmacology. Supplement
|
2008
|
tom 59
|
nr 6
243-251
5
Content available remote Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation
75%
Jastrzebski D. , Gumola A. , Gawlik R. , Kozielski J.
Journal of Physiology and Pharmacology. Supplement
|
2006
|
tom 57
|
nr 4
139-148
EN
The aim of the study was to estimate the level of dyspnea and quality of life in patients with pulmonary fibrosis after 6 weeks' respiratory rehabilitation. The study comprised of 31 patients (F/M-12/19) with interstitial lung diseases (21 with idiopathic interstitial pneumonia, 4 with lung fibrosis due to allergic alveolitis, 4 with lung fibrosis due to collagenosis, 2 with lung fibrosis due to silicosis) who successfully finished the rehabilitation program. Each patient underwent an intensive (every day for 30 min) inpatient pulmonary rehabilitation program of an average length of 4 wk, continued later at home for up to 12 wk. The program consisted of respiratory muscle training and bicycle riding to the limits of the patient's tolerance. Dyspnea (MRC, OCD, BDI and Borg scale) and the quality of live (SF-36, St. George's Respiratory Questionnaire) were assessed at the time of admission and discharge. Rehabilitation caused dyspnea sensation to diminish (Borg scale: 2.97 before vs. 2.19 after). Some domains of the quality of life in SF-36 questionnaire (Role-Physical 40.6 vs. 60.2) and St. George's Respiratory Questionnaire (activity: 52 vs. 45, impact 47 vs. 40 and total 47 vs. 42) also were improved compared with the pre-rehabilitation results. We conclude that 12 weeks of combined inpatient and home-based rehabilitation programme improves the quality of live and sensation of dyspnea in patients with interstitial lung disease, despite changes in pulmonary function tests.
6
Content available remote Prognostic risk factors in patients with interstitial lung disease referred for lung transplantation
75%
Jastrzebski D. , Kozielski J. , Nowak J. , Zielinska-Les I. , Ziora D. , Szulik B. , Wojarski J. , Zakliczynski M. , Zembala M.
Journal of Physiology and Pharmacology. Supplement
|
2005
|
tom 56
|
nr 4
107-113
EN
The aim of the study was to identify prognostic factors that would differentiate patients with interstitial lung disease between those with and without a chance to survive until lung transplantation. A retrospective study was performed in patients with interstitial lung disease referred for lung transplantation between September 1999 and April 2005. The analysis included the demographic data, the time from referral to transplantation, the functional tests (FVC, FEV1, FEV1%VC, the PaO2 at rest and after oxygen supplementation via a nasal catheter), the count of NYHA functional classes, the left ventricular ejection fraction (EF), the distance covered during a 6-min walk test, and the pathogens in the respiratory tract. The patients were divided into two groups: Group 1 - lung transplant candidates who survived until the successful procedure and Group 2 - lung transplant candidates who died while on the waiting list. There were statistical differences between the two groups in PaO2 after supplementation (P=0.005), EF (P=0.002), and the 6-min walk distance (P=0.001). It appears that simple functional tests of the cardiorespiratory system may define survival of patients with interstitial lung disease waiting for lung transplantation.
7
The role of leukotrienes in the pathogenesis of systemic sclerosis
63%
Chwiesko-Minarowska S. , Kowal K. , Bielecki M. , Kowal-Bielecka O.
Folia Histochemica et Cytobiologica
|
2012
|
tom 50
|
nr 2
8
Content available remote Left ventricular dysfunction in patients with interstitial lung diseases referred for lung transplantation
63%
Jastrzebski D. , Nowak J. , Ziora D. , Wojarski J. , Czyzewski D. , Kozielski J. , Polonski L. , Zembala M.
Journal of Physiology and Pharmacology. Supplement
|
2007
|
tom 58
|
nr 5
9
Content available remote Induced sputum in patients with interstitial lung disease: a non-invasive surrogate for certain parameters in bronchoalveolar lavage fluid
63%
Sobiecka M. , Kus J. , Demkow U. , Filewska M. , Jozwik A. , Radwan-Rohrenschef P. , Chorostowska-Wynimko J.
Journal of Physiology and Pharmacology. Supplement
|
2008
|
tom 59
|
nr 6
645-657
10
Content available remote Upregulation of Th1 cytokine profile in bronchoalveolar lavage fluid of patients with hypersensitivity pneumonitis
63%
Mroz R. M. , Korniluk M. , Stasiak-Barmuta A. , Chyczewska E.
Journal of Physiology and Pharmacology. Supplement
|
2008
|
tom 59
|
nr 6
499-505
11
Content available remote Angiogenic activity of sera from silicosis and pulmonary Langerhans cell histiocytosis patients in relation to lung function tests
63%
Zielonka T. M. , Demkow U. , Filewska M. , Bialas-Chromiec B. , Zycinska K. , Radzikowska E. , Korzeniewska M. , Wardyn K. A. , Kus J. , Skopinska-Rozewska E.
Journal of Physiology and Pharmacology. Supplement
|
2008
|
tom 59
|
nr 6
781-789
12
Enhanced expression of Fas Ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs)
51%
Kopinski P. , Balicka-Slusarczyk B. , Dyczek A. , Szpechcinski A. , Przybylski G. , Jarzemska A. , Wandtke T. , Jankowski M. , Iwaniec T. , Chorostowska-Wynimko J.
Folia Histochemica et Cytobiologica
|
2011
|
tom 49
|
nr 4
13
Content available remote TNFalpha and INFgamma inducing capacity of sera from patients with interstitial lung disease in relation to its angiogenesis activity
51%
Zielonka T. M. , Demkow U. , Puscinska E. , Golian-Geremek A. , Filewska M. , Zycinska K. , Bialas-Chromiec B. , Wardyn K. A. , Skopinska-Rozewska E.
Journal of Physiology and Pharmacology. Supplement
|
2007
|
tom 58
|
nr 5
14
Content available Choroby współistniejące w przypadku śródmiąższowych chorób płuc u dorosłych mieszkańców województwa śląskiego
51%
Niewiadomska E. , Kowalska M. , Zejda J. E.
Medycyna Pracy
|
2016
|
tom 67
|
nr 6
751-763
EN
Background Interstitial lung diseases form a group of chronic diseases associated with a significant worsening of the quality of life. Proper management of these diseases involves the recognition and treatment of comorbidities, so it implies high direct and indirect costs of therapy. The lack of epidemiological data on the total incidence of interstitial diseases in Poland, as well as of information on their increasing incidence in other European countries justify investigations into epidemiological situation in the Silesian voivodeship (the southern region of Poland). Material and Methods In a descriptive study registered data provided by the National Health Found in 2006–2010 were used to assess the temporal variability of standardized incidence rates. A data set included interstitial lung diseases and comorbidities in adults aged ≥ 19 years, residents of the Silesian voivodeship. Results In the period under study standardized incidence ratios for interstitial lung disease declined from 9.7/100 000 adult population to 7.8/100 000 adult population. The most prevalent comorbidities included cardio-vascular diseases, chronic and infectious respiratory diseases, metabolic diseases and musculoskeletal and connective tissue diseases. Comorbidities were found more frequently in older people ≥ 65 years, except for sarcoidosis, which was four times more prevalent in younger people (19–64 years) compared to older patients. The estimated costs of treatment of the analysed diseases reached more than 50 mln zlotys (12 mln dollars) per year. Conclusions A small but systematic decrease in the value of the standardized incidence rate for interstitial lung disease has been shown within the range of 9.7–7.8/100 000 adult inhabitants. The most frequent comorbidities included cardiovascular or chronic and infectious respiratory diseases. The high cost of therapy of interstitial lung diseases was largely related to simultaneous treatment of comorbidities. Med Pr 2016;67(6):751–763
PL
Wstęp Śródmiąższowe choroby płuc to grupa chorób przewlekłych wpływająca na znaczne pogorszenie jakości życia. Postępowanie terapeutyczne w przypadku tych chorób wymaga także rozpoznania i leczenia chorób współistniejących, dlatego jest obarczone wysokimi kosztami bezpośrednimi i pośrednimi. Brak danych epidemiologicznych dotyczących częstości występowania chorób śródmiąższowych w naszym kraju, jak również doniesienia o rosnącej zapadalności w innych krajach europejskich uzasadniają poznanie sytuacji epidemiologicznej w odniesieniu do tych chorób, z uwzględnieniem chorób współistniejących. Materiał i metody Na podstawie danych rejestrowych z lat 2006–2010, udostępnionych przez Narodowy Fundusz Zdrowia (NFZ), oceniono czasowe zróżnicowanie standaryzowanych współczynników opisujących liczbę nowych zachorowań oraz przedstawiono strukturę chorób współistniejących. Dane dotyczyły mieszkańców województwa śląskiego w wieku ≥ 19 lat. Wyniki Wykazano niewielki, lecz systematyczny, spadek wartości standaryzowanego współczynnika zachorowań na śródmiąższowe choroby płuc w zakresie 9,7–7,8/100 000 dorosłych mieszkańców. Wśród chorób współistniejących dominowały choroby układu krążenia, przewlekłe i zakaźne choroby układu oddechowego, choroby metaboliczne oraz choroby układu mięśniowo-szkieletowego i tkanki łącznej. Choroby towarzyszące występowały częściej wśród osób starszych (≥ 65 lat), z wyjątkiem sarkoidozy, w której przypadku liczba rejestrowanych chorób współistniejących była 4-krotnie większa u młodszych osób (19–64-letnich). Koszty leczenia wybranych chorób układu oddechowego w województwie śląskim sięgają ponad 50 mln złotych rocznie. Wnioski Wykazano niewielki spadek wartości standaryzowanego współczynnika zachorowań na śródmiąższowe choroby płuc u dorosłych mieszkańców województwa śląskiego. Wśród najczęściej rejestrowanych chorób współtowarzyszących znajdują się choroby układu krążenia oraz przewlekłe i zakaźne choroby układu oddechowego. Wysokie koszty terapii chorób śródmiąższowych są m.in. skutkiem leczenia chorób współistniejących. Med. Pr. 2016;67(6):751–763
15
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 bronchoalveolar lavage [BAL] in patients with sarcoidosis, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis
51%
Kucejko W. , Chyczewska E. , Naumnik W. , Ossolinska M.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 2
225-230
16
Expression of insulin-like growth factor-I [IGF-I] in alveolar macrophages and lymphocytes obtained by bronchoalveolar lavage [BAL] in interstitial lung diseases [ILD]. Assessment of IGF-I as a potential local mitogen and antiapoptotic cytokine
51%
Kopinski P. , Sladek K. , Szczeklik J. , Soja J. , Szlubowski A. , Balicka-Slusarczyk B. , Lackowska B. , Plato M. , Szpechcinski A.
Folia Histochemica et Cytobiologica
|
2006
|
tom 44
|
nr 4
first rewind previous Strona / 1 next fast forward last
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.